- Home
- FMY vs IMMX Comparison
FMY vs IMMX Comparison
Compare FMY & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- IMMX
- Stock Information
- Founded
- FMY 2005
- IMMX 2014
- Country
- FMY United States
- IMMX United States
- Employees
- FMY N/A
- IMMX N/A
- Industry
- FMY Finance/Investors Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- FMY Finance
- IMMX Health Care
- Exchange
- FMY Nasdaq
- IMMX Nasdaq
- Market Cap
- FMY 52.1M
- IMMX 51.1M
- IPO Year
- FMY N/A
- IMMX 2021
- Fundamental
- Price
- FMY $12.18
- IMMX $1.38
- Analyst Decision
- FMY
- IMMX Strong Buy
- Analyst Count
- FMY 0
- IMMX 1
- Target Price
- FMY N/A
- IMMX $7.00
- AVG Volume (30 Days)
- FMY 10.1K
- IMMX 148.3K
- Earning Date
- FMY 01-01-0001
- IMMX 11-11-2024
- Dividend Yield
- FMY 6.98%
- IMMX N/A
- EPS Growth
- FMY N/A
- IMMX N/A
- EPS
- FMY N/A
- IMMX N/A
- Revenue
- FMY N/A
- IMMX N/A
- Revenue This Year
- FMY N/A
- IMMX N/A
- Revenue Next Year
- FMY N/A
- IMMX $200.00
- P/E Ratio
- FMY N/A
- IMMX N/A
- Revenue Growth
- FMY N/A
- IMMX N/A
- 52 Week Low
- FMY $10.71
- IMMX $1.26
- 52 Week High
- FMY $12.17
- IMMX $7.75
- Technical
- Relative Strength Index (RSI)
- FMY 39.85
- IMMX 37.40
- Support Level
- FMY $12.12
- IMMX $1.26
- Resistance Level
- FMY $12.49
- IMMX $1.80
- Average True Range (ATR)
- FMY 0.18
- IMMX 0.16
- MACD
- FMY -0.03
- IMMX -0.00
- Stochastic Oscillator
- FMY 10.00
- IMMX 22.22
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.